Indrayani Biotech Ltd has informed BSE that the meeting of the Board of Directors inter alia, to consider and approve unaudited financial results (standalone and consolidated) for quarter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech has informed BSE that its Board Meeting scheduled for November 14, 2025 has been postponed. The meeting was originally called to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and half-year ended September 30, 2025. The deferral was triggered because the Audit Committee could not adopt the results — it needed additional information and clarification from the Management on certain line items. Both the Audit Committee meeting and the subsequent Board meeting stand postponed. The company has stated it is working to provide the required inputs and will communicate the revised date to the exchange shortly.
Investors will have to wait longer for the Q2/H1 FY26 numbers. While no specific issue is disclosed, the Management's inability to provide clarifications on certain line items to the Audit Committee may raise minor governance or transparency concerns among shareholders.